Abstract

Predicting mortality in dialysis patients based on low intact parathyroid hormone levels is difficult, because aluminum intoxication, malnutrition, older age, race, diabetes, or peritoneal dialysis may influence these levels. We investigated the clinical implications of low parathyroid hormone levels in relation to the mortality of dialysis patients using sensitive, stratified, and adjusted models and a nationwide dialysis database. We analyzed data from 2005 to 2012 that were held on the Taiwan Renal Registry Data System, and 94,983 hemodialysis patients with valid data regarding their intact parathyroid levels were included in this study. The patient cohort was subdivided based on the intact parathyroid hormone and alkaline phosphatase levels. The mean hemodialysis duration within this cohort was 3.5 years. The mean (standard deviation) age was 62 (14) years. After adjusting for age, sex, diabetes, the hemodialysis duration, serum albumin levels, hematocrit levels, calcium levels, phosphate levels, and the hemodialysis treatment adequacy score, the single-pool Kt/V, the crude and adjusted all-cause mortality rates increased when alkaline phosphatase levels were higher or intact parathyroid hormone levels were lower. In general, at any given level of serum calcium or phosphate, patients with low intact parathyroid hormone levels had higher mortality rates than those with normal or high iPTH levels. At a given alkaline phosphatase level, the hazard ratio for all-cause mortality was 1.33 (p < 0.01, 95% confidence interval 1.27–1.39) in the group with intact parathyroid hormone levels < 150 pg/mL and serum calcium levels > 9.5 mg/dL, but in the group with intact parathyroid hormone levels > 300 pg/mL and serum calcium levels > 9.5 mg/dL, the hazard ratio was 0.92 (95% confidence interval 0.85–1.01). Hence, maintaining albumin-corrected high serum calcium levels at > 9.5 mg/dL may correlate with poor prognoses for patients with low intact parathyroid hormone levels.

Highlights

  • Chronic kidney disease (CKD)-mineral and bone disorder (MBD) increases morbidity and mortality in end-stage renal disease (ESRD) patients.[1]

  • A total of 94,983 HD patients with valid data relating to intact PTH (iPTH) and alkaline phosphatase (ALP) levels were included in this study

  • We divided each categories of iPTH by a cut-off value of ALP 120 U/L

Read more

Summary

Introduction

Chronic kidney disease (CKD)-mineral and bone disorder (MBD) increases morbidity and mortality in end-stage renal disease (ESRD) patients.[1] Renal osteodystrophy may be initiated at the onset of CKD because of an increase in urinary phosphate (P) excretion. Vascular calcification may be associated with low PTH levels in ESRD patients,[4,5] and coronary artery disease is the leading cause of death in these patients. Normal PTH levels do not prevent low turnover disease.[6] In addition, low PTH levels may be linked to hypercalcemia.[7] Hypercalcemia may increase the mortality of ESRD patients with abnormal PTH levels at any given serum P level.[8] risk stratification of patients based on the Ca or P levels as well as the PTH levels is crucial.[9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call